PD-1 inhibitor, mainly putting brakes on unrestricted cytotoxic T effector function, was first approved by U.S. Food and Drug Administration for the treatment of unresectable/metastatic melanoma cancer and non-small-cell lung cancer second-line alternative supported by National Comprehensive Cancer Network guideline [57]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.